Logo-jrip
Submitted: 10 Nov 2022
Accepted: 20 Feb 2023
ePublished: 27 Apr 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2023;12(2): e32192.
doi: 10.34172/jrip.2023.32192

Scopus ID: 85159023936
  Abstract View: 970
  PDF Download: 497

Meta-analysis

The association between statin administration and renal cell carcinoma; a systematic review and meta-analysis

Pantea Ramezannezhad 1 ORCID logo, Mohammadreza Khosravifarsani 2* ORCID logo

1 Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
*Corresponding Author: Mohammadreza Khosravifarsani, Email: khosravi.mr@skums.ac.ir

Abstract

Introduction: Renal cell carcinoma (RCC) is the most prevalent renal cancer in adults, with a rising global incidence. There has long been an ambiguity about the effect of statin administration on the incidence of RCC. The present meta-analysis aims to evaluate the relationship between statin usage and RCC.

Materials and Methods: Cochrane, Web of Science, Scopus, and PubMed databases, as well as the Google Scholar search engine, were queried for relevant articles. The data were statistically analyzed by STATA 14 software. The significance level of the tests was considered P<0.05.

Results: In 15 reviewed articles, 46 735 subjects used statin, and 673 752 did not. The odds ratio (OR) between statin usage and the risk incidence of RCC was 0.86 (OR: 0.86; 95% CI: 0.63, 1.17) overall and estimated as 0.94 (OR: 0.94; 95% CI: 0.69, 1.28) in males and 0.92 (OR: 0.92; 95% CI: 0.66, 1.28) in females. The odds ratio of statin administration and the incidence risk of RCC was 0.74 (OR: 0.74; 95% CI: 0.37, 1.49) in case-control and 0.96 (OR: 0.96; 95% CI: 0.79, 1.17) in cohort studies. In addition, the impact of statin usage on overall survival (OS) in RCC was 0.65 (HR: 0.65; 95% CI: 0.53, 0.80), and this relationship was statistically significant. However, the effect of statin usage was 0.68 (HR: 0.68; 95% CI: 0.45, 1.02) on progression-free survival (PFS) and 1.24 (OR: 1.24; 95% CI: 0.66, 2.32) on disease progression (DP), and these relationships were statistically non-significant.

Conclusion: The OS of RCC patients was 35% higher in statin users than in non-users. However, no relationship between statin usage and the incidence risk of RCC was found.

Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (CRD42023393647).


Implication for health policy/practice/research/medical education:

Our meta-analysis showed that statin administration was not associated with the risk of renal cell carcinoma (RCC) development. Moreover, the patient gender and study type did not affect the relationship between statin administration and the incidence risk of RCC. However, the overall survival in administration was 35% higher in statin users compared to non-users.

Please cite this paper as: Ramezannezhad P, Khosravifarsani M. The association between statin administration and renal cell carcinoma; a systematic review and meta-analysis. J Renal Inj Prev. 2023; 12(2): e32192. doi: 10.34172/jrip.2023.32192.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 971

Your browser does not support the canvas element.


PDF Download: 497

Your browser does not support the canvas element.